BCA-1 non-invasive test
Always at the cutting-edge of innovation in genetic diagnosis, AdGeniX recently started to offer the first non-invasive bladder cancer detection test with a sensitivity and specificity equivalent to cystoscopy.
The BCA-1 test is derived from patented research conducted by Array Genomics and will shortly be available in Europe for bladder-cancer patients and urologists.
A key player in the international development of Array Genomics, AdGeniX invites those who so wish to add their innovative technology to its range of healthcare products and services.
AdGeniX can help innovative firms on the DNA genetic testing market to promote their business in France and in French-speaking countries.
At AdGeniX, we can draw on our experience of working with researchers and healthcare organisations to accelerate growth for companies offering innovative healthcare products and services for individuals and market players.
You are very welcome to contact our staff in order to discuss your genetic testing needs or if you are looking for a development partner.